Expanding frontiers in cardiometabolic therapy: SGLT2 inhibitors and GLP-1 receptor agonists

29 August 2026 (18:06 - 18:18)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Valerie Schini-Kerth

INSERM, University of Strasbourg, CRBS, Strasbourg (France)

4 More presentations in this session

Presentation thumbnail

Targeting inflammasome axis and NLRP3 inhibitors and IL-1 blockade in cardiovascular disease

Professor P. Libby (Boston, US)

Presentation thumbnail

Targeting IL-6 signalling from biological rationale to cardiovascular outcome trials

Doctor P. Ridker (Boston, US)

Presentation thumbnail

Heart failure and immune-mediated syndrome: new insights and emerging targets

Professor J. Hill (Dallas, US)

Presentation thumbnail

Frontiers in anti-inflammatory therapies - discussion

Access the full session

Session thumbnail

Frontiers in anti-inflammatory therapies

The Event

Event poster

ESC Congress 2026

29 August 2026 18:06 CET

You may be interested in

Congress Presentation

Monocytes from CAD patients displayed M1 phenotype and released inflammatory mediators inducing endothelial dysfunction: M1 resolution and endothelial protection by SGLT2i + GLP-1Ra synergism

29 August 2025

Congress Presentation

The sodium–glucose co-transporter 2 inhibitor canagliflozin, attenuates cardiac fibrosis and function in inflammatory dilated cardiomyopathy

28 August 2026

Congress Presentation

Cardiovascular outcomes in diabetic patients treated with SGLT2i and GLP1-RA: systematic review and meta-analysis

19 May 2025

Congress Presentation

Targeting inflammation and immunity in cardiovascular disease

30 August 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources